Insmed Q3 revenue tops $524 million; Brinsupri, Arikayce guidance raised, Japan launch underway
Insmed raised full-year guidance for both drugs after strong Q3 growth and advanced three initiated Phase 3 TPIP trials, with a fourth planned for 2027.
SEC filing (7)